DWP212525

Phase 1Small molecule

Daewoong Pharmaceutical Co. LTD.

DWP212525 is one of 8 small molecule programs targeting Double-blind. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Double-BlindRecruiting

Double-BlindPhase 1

Recruiting

Competition

Competitive Landscape

10 competitors in Double-Blind

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

1 2

Albenza

IImpax Laboratories, LLC

Phase 3

1 3

Everolimus and Lonafarnib

BBoston Children's Hospital

Phase 3

1 4

Inosine Pranobex

NNewport Pharmaceuticals International

Preclinical

2 5

DWP212525

Daewoong Pharmaceutical Co. LTD.

Phase 1

1 6

PORT-77

PPortal Therapeutics, Inc.

Phase 1

1 7

Western Therapy

JJiangxi Qingfeng Pharmaceutical Co. Ltd.

Preclinical

1 8

Interferon Alfa-N3

IInterferon Sciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Double-blind1 trial

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers

Recruiting· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 1·NCT06736587·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DWP212525. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DWP212525 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DWP212525. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daewoong Pharmaceutical Co. LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Daewoong Pharmaceutical Co. LTD.

DWP212525

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Double-blind1 trial

References

Drug Info

Quick Facts

Related News